Hatefi Masoud, Ahmadi Mohammad Reza Hafezi, Rahmani Asghar, Dastjerdi Masoud Moghadas, Asadollahi Khairollah
Department of Neurosurgery, Faculty of Medicine, Ilam University of Medical Sciences, Ilam, Iran.
Department of Pathology, Faculty of Medicine, Ilam University of Medical Sciences, Ilam, Iran.
World Neurosurg. 2018 Jun;114:e785-e791. doi: 10.1016/j.wneu.2018.03.081. Epub 2018 Mar 19.
Osteoporosis is one of the most common problems of patients with spinal cord injuries (SCIs). The current study aimed to evaluate the antiosteoporotic effects of curcumin on densitometry parameters and biomarkers of bone turnovers among patients with SCI.
The current controlled clinical trial was conducted among 100 patients with SCI referred to an outpatient clinic of rehabilitation in Ilam City, Iran, in 2013-2015. The intervention group received 110/mg/kg/day curcumin for 6 months and the control group received placebo. Bone mineral density (BMD) was measured in all patients. The level of procollagen type I N-terminal propeptide, serum carboxy-terminal telopeptide of type I collagen, osteocalcin, and bone-specific alkaline phosphates were compared before and after study.
BMD indicators of lumbar, femoral neck, and total hip in the control group significantly decreased compared with the beginning of study. However, in the curcumin group, a significant increase was observed in BMD indicators of lumbar, femoral neck, and hip at the end of study compared with the beginning. There was also a significant difference between interventional and control groups for the mean BMD of femoral neck and hip at the end of study (0.718 ± 0.002 g/cm vs. 0.712 ± 0.003 g/cm and 0.742 ± 0.031 g/cm vs. 0.692 ± 0.016 g/cm, respectively).
Curcumin, via modulation of densitometry indices and bone resorption markers, showed inhibitory effects on the process of osteoporosis. Treatment with curcumin was significantly associated with a decrease in the osteoporosis progression and bone turnover markers of patients with SCI after 6 months.
骨质疏松是脊髓损伤（SCI）患者最常见的问题之一。本研究旨在评估姜黄素对SCI患者骨密度参数和骨转换生物标志物的抗骨质疏松作用。
2013 - 2015年，在伊朗伊拉姆市一家康复门诊对100例SCI患者进行了这项对照临床试验。干预组患者接受110毫克/千克/天的姜黄素治疗6个月，对照组接受安慰剂治疗。测量了所有患者的骨密度（BMD）。比较了研究前后I型前胶原N端前肽、I型胶原血清C端肽、骨钙素和骨特异性碱性磷酸酶的水平。
与研究开始时相比，对照组的腰椎、股骨颈和全髋部的骨密度指标显著下降。然而，在姜黄素组中，研究结束时腰椎、股骨颈和髋部的骨密度指标与开始时相比显著增加。研究结束时，干预组和对照组在股骨颈和髋部的平均骨密度之间也存在显著差异（分别为0.718±0.002克/平方厘米对0.712±0.003克/平方厘米和0.742±0.031克/平方厘米对0.692±0.016克/平方厘米）。
姜黄素通过调节骨密度指标和骨吸收标志物，对骨质疏松过程显示出抑制作用。姜黄素治疗与SCI患者6个月后骨质疏松进展和骨转换标志物的降低显著相关。
